Get started
Author

Kevin Duffy

ORCID: 0009-0000-6246-5901
Observed ORCID: 0009-0000-6246-5901
OpenAlex ID: A5114043124
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
2021 · Shaun Cordoba, Shimobi Onuoha, et al. · Nature Medicine · 302
PDF
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma
2023 · Claire Roddie, Lazaros J. Lekakis, et al. · Blood · 100
PDF
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al. · Clinical Cancer Research · 8
Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process
2021 · Abigail Culshaw, Frederick Arce Vargas, et al. · Blood · 1
Data from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S3 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S1 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S2 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S7 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S6 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S4 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S5 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Supplementary Methods from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Figure S8 from Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al.
Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
2026 · Daan G. Knapen, Claudia A.J. van Winkel, et al. · Molecular Cancer Therapeutics
Supplementary Table 1 from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al.
Data from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al.
Works count: 17
Citation count: 411
H-index: 3
I10-index: 2
Year
Topic
Type